308 related articles for article (PubMed ID: 26780555)
41. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
42. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
43. Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancers.
Menkiszak J; Chudecka-Głaz A; Gronwald J; Cymbaluk-Płoska A; Celewicz A; Świniarska M; Wężowska M; Bedner R; Zielińska D; Tarnowska P; Jakubowicz J; Kojs Z
J Ovarian Res; 2016 Feb; 9():11. PubMed ID: 26928677
[TBL] [Abstract][Full Text] [Related]
44. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal.
Kotsopoulos J; Lubinski J; Gronwald J; Menkiszak J; McCuaig J; Metcalfe K; Foulkes WD; Neuhausen SL; Sun S; Karlan BY; Eisen A; Tung N; Olopade OI; Couch FJ; Huzarski T; Senter L; Bordeleau L; Singer CF; Eng C; Fruscio R; Pal T; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1351-1358. PubMed ID: 35477169
[TBL] [Abstract][Full Text] [Related]
45. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies.
Negri E; Tzonou A; Beral V; Lagiou P; Trichopoulos D; Parazzini F; Franceschi S; Booth M; La Vecchia C
Int J Cancer; 1999 Mar; 80(6):848-51. PubMed ID: 10074916
[TBL] [Abstract][Full Text] [Related]
46. Changes in health-related behaviours following BRCA 1/2 genetic testing: the case of hormone replacement therapy.
Rouleau I; Chiquette J; Plante M; Simard J; Dorval M
J Obstet Gynaecol Can; 2004 Dec; 26(12):1059-66. PubMed ID: 15607041
[TBL] [Abstract][Full Text] [Related]
47. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk.
Mills PK; Riordan DG; Cress RD; Goldsmith DF
Cancer Detect Prev; 2005; 29(2):124-32. PubMed ID: 15829372
[TBL] [Abstract][Full Text] [Related]
48. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
49. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality.
O'Meara ES; Rossing MA; Daling JR; Elmore JG; Barlow WE; Weiss NS
J Natl Cancer Inst; 2001 May; 93(10):754-62. PubMed ID: 11353785
[TBL] [Abstract][Full Text] [Related]
50. Menopausal hormone therapy for BRCA mutation carriers: A case for precision medicine.
Kotsopoulos J; Narod SA
Maturitas; 2024 May; 183():107886. PubMed ID: 37980268
[No Abstract] [Full Text] [Related]
51. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
Heemskerk-Gerritsen BA; Seynaeve C; van Asperen CJ; Ausems MG; Collée JM; van Doorn HC; Gomez Garcia EB; Kets CM; van Leeuwen FE; Meijers-Heijboer HE; Mourits MJ; van Os TA; Vasen HF; Verhoef S; Rookus MA; Hooning MJ;
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25788320
[TBL] [Abstract][Full Text] [Related]
52. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
[TBL] [Abstract][Full Text] [Related]
53. Risk factors for endometrial cancer among women with a BRCA1 or BRCA2 mutation: a case control study.
Segev Y; Rosen B; Lubinski J; Gronwald J; Lynch HT; Moller P; Kim-Sing C; Ghadirian P; Karlan B; Eng C; Gilchrist D; Neuhausen SL; Eisen A; Friedman E; Euhus D; Ping S; Narod SA;
Fam Cancer; 2015 Sep; 14(3):383-91. PubMed ID: 25838159
[TBL] [Abstract][Full Text] [Related]
54. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
55. Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age.
Tea MK; Weghofer A; Wagner K; Singer CF
Maturitas; 2013 Jun; 75(2):148-51. PubMed ID: 23528734
[TBL] [Abstract][Full Text] [Related]
56. The role of personal health concerns and knowledge of the health effects of hormone replacement therapy (HRT) on the ever use of HRT by menopausal women, aged 50-54 years.
MacDougall LA; Barzilay JI; Helmick CG
J Womens Health Gend Based Med; 1999 Nov; 8(9):1203-11. PubMed ID: 10595334
[TBL] [Abstract][Full Text] [Related]
57. Factors modifying the association between hormone-replacement therapy and breast cancer risk.
Pesch B; Ko Y; Brauch H; Hamann U; Harth V; Rabstein S; Pierl C; Fischer HP; Baisch C; Justenhoven C; Ranft U; Brüning T
Eur J Epidemiol; 2005; 20(8):699-711. PubMed ID: 16151884
[TBL] [Abstract][Full Text] [Related]
58. Variability of breast cancer risk in observational studies of hormone replacement therapy: a meta-regression analysis.
Garbe E; Levesque L; Suissa S
Maturitas; 2004 Mar; 47(3):175-83. PubMed ID: 15036487
[TBL] [Abstract][Full Text] [Related]
59. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
[TBL] [Abstract][Full Text] [Related]
60. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
